Search
Bumadizone
go.drugbank.com/drugs/DB13286ApprovedBumadizone has been approved for use in Germany and Austria, it is a drug with anti-inflammatory, antipyretic, and analgesic properties, and was marketed for the treatment of both rheumatoid arthritis … Its use is restricted to these conditions, due to risks this drug poses [L5650].
Setiptiline
go.drugbank.com/drugs/DB09304ExperimentalIn Japan, the company Mochida started its commercialization for the treatment of depression started in 1989. … Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA).
Fluoride ion
go.drugbank.com/drugs/DB11257ApprovedInvestigationalFluoride ions are found in various minerals but are only present in trace amounts in water. … Having a chemical formula of F−, fluoride ion is the simplest inorganic, monatomic anion of fluorine with basic properties. It is considered a trace element.
RAPA-501-Allo
go.drugbank.com/drugs/DB15890InvestigationalRAPA-501-ALLO is composed of T-cells extracted from healthy volunteers; these cells are then reprogrammed _ex vivo_ in a process that involves de-differentiation and re-differentiation.[L16483]
Col-118
go.drugbank.com/drugs/DB05778InvestigationalIt is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue. … Col-118 is a unique formulation and presentation of Brimonidine, which is a selective alpha-2 adrenergic receptor agonist.
EGS21
go.drugbank.com/drugs/DB05056ExperimentalEGS21(TM) is a beta-D-glucosylceramide (GC) compound. It is a potential therapeutic for treating immune mediated disorders. … GC is a glycolipid that has been shown by Enzo scientists and collaborators to act as an anti-inflammatory agent in animal model systems, and therefore is being evaluated as an important candidate
Upanovimab
go.drugbank.com/drugs/DB16505InvestigationalUpanovimab (SCTA01) was under investigation in clinical trials (NCT04683328, NCT04644185, NCT04709328 and NCT05156645) to evaluate its safety and efficacy in patients with severe COVID-19
INM005
go.drugbank.com/drugs/DB16499InvestigationalINM005 was under investigation in clinical trials for the treatment of COVID-19. It was studied for pharmacokinetics, efficacy, and safety in a completed trial (NCT04494984).
NKG2D-ACE2 CAR-NK Cell
go.drugbank.com/drugs/DB15727InvestigationalThese cells are prepared as universal off-the-shelf CAR-NK cells from cord blood with NKG2D-ACE2 proteins engineered as part of the CARs; the cell secretes IL-15 and GM-CSF. … The IL-15 superagonist increases the activity of NK cells and improves their target cytotoxicity. The GM-CSF acts as a neutralizer for the CAR-T cell-mediated cytokine release and neurotoxicity.
Tezosentan
go.drugbank.com/drugs/DB06558InvestigationalTezosentan was initially developed for vasodilation in patients with acute heart failure but studies have shown that it does not assist in the treatment of dyspnea or prevent cardiovascular events. … Tezosentan is an intravenous endothelin receptor A/B antagonist.